(OLMA)
NMS – Real vaqt narxi. Valyuta: USD
13.67
-0.45 (-3.19%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
13.67
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 5:20 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NMS – Real vaqt narxi. Valyuta: USD
13.67
-0.45 (-3.19%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
13.67
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 5:20 PM EDT
Olema Pharmaceuticals, Inc., klinik tadqiqot bosqichidagi biotexnologiya kompaniyasi bo'lib, ayollar saratonini davolash usullarini kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniyaning asosiy dori nomzodi palazestrant bo'lib, u estrogen retseptorlari (ER) antagonisti va selektiv ER degraderidir. Ushbu preparat takroriy, mahalliy ilg'or yoki metastatik ER-musbat, inson epidermal o'sish omili retseptorlari 2-negativ ko'krak bezi saratonini davolash uchun III bosqich klinik sinovdan o'tmoqda; OPERA-01 - bu palazestrantning ikkinchi/uchinchi qatorda ER+/HER2- metastatik ko'krak bezi saratoni uchun monoterapiya sifatida muhim III bosqich klinik sinovi; va palazestrant CDK4/6 ingibitorlari bilan, fosfoinozitid 3 kinaza alfa (PI3Ka) ingibitori alpelisib, rapamitsinning mexanistik maqsadi ingibitori va CDK4 ingibitori bilan birgalikda, ER+/HER2- ilg'or yoki metastatik ko'krak bezi saratonini davolash uchun Ib/2 bosqich klinik sinovidan o'tmoqda. Shuningdek, kompaniya OP-3136ni ishlab chiqmoqda, bu og'iz orqali yuboriladigan kichik molekula bo'lib, u ko'krak bezi va boshqa qattiq o'smali saraton kasalliklari bo'lgan bemorlarda I bosqich klinik sinovlarida bo'lgan KAT6ni kuchli va selektiv ravishda inhibe qiladi. Kompaniya ilgari CombiThera, Inc. nomi bilan tanilgan va 2009 yil mart oyida Olema Pharmaceuticals, Inc. nomini olgan. Olema Pharmaceuticals, Inc. 2006 yilda tashkil etilgan va San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David C. Myles Ph.D. | Chief Discovery & Non-Clinical Development Officer |
| Dr. Kamesh Kuchimanchi Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Dr. Mark Shilkrut M.D., Ph.D. | Senior Vice President of Clinical Development |
| Dr. Naseem Zojwalla M.D. | Chief Medical Officer |
| Dr. Sean P. Bohen M.D., Ph.D. | President, CEO, Interim Principal Financial Officer & Director |
| Mr. Richard Hernandez | Senior Vice President of Clinical Development Operations |
| Mr. Shane William Charles Kovacs M.B.A. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-16 | S-8 | olma-20260316.htm |
| 2026-01-30 | 8-K | d126625d8k.htm |
| 2026-01-12 | 8-K | olma-20260112.htm |
| 2025-12-11 | S-3ASR | d848104ds3asr.htm |
| 2025-11-19 | 8-K | d46182d8k.htm |
| 2025-11-18 | 8-K | d86905d8k.htm |
| 2025-11-10 | 8-K | olma-20251110.htm |
| 2025-10-20 | 8-K | olma-20251018.htm |
| 2025-09-02 | 8-K | olma-20250902.htm |
| 2025-08-11 | 10-Q | olma-20250630.htm |
| Consultant |
| Ms. Courtney O'Konek | Vice President of Corporate Communications |
| Ms. Julie Dexter | Senior VP & Head of People |
| Ms. Shawnte M. Mitchell J.D. | Chief Legal Officer & Corporate Secretary |